Table 1.
Patient characteristics according to the lymphovascular invasion status.
| Lymphovascular invasion status | |||||
|---|---|---|---|---|---|
| Negative (N=4173, 91.6%) | Positive (N=381, 8.4%) | p-value | |||
| N | % | N | % | ||
| Age, years | <0.001 | ||||
| <50 | 1905 | 89.9 | 213 | 10.1 | |
| ≥50 | 2268 | 93.1 | 168 | 6.9 | |
| T stage | <0.001 | ||||
| 1 | 3268 | 94.0 | 210 | 6.0 | |
| 2 | 871 | 84.6 | 159 | 15.4 | |
| 3 | 34 | 73.9 | 12 | 26.1 | |
| N stage | <0.001 | ||||
| N0 | 3450 | 95.2 | 174 | 4.8 | |
| N1mi | 181 | 84.2 | 34 | 15.8 | |
| N1 | 432 | 80.6 | 104 | 19.4 | |
| N2 | 82 | 68.3 | 38 | 31.7 | |
| N3 | 28 | 47.5 | 31 | 52.5 | |
| Histologic Grade | <0.001 | ||||
| 1 | 1151 | 96.6 | 40 | 3.4 | |
| 2 | 2118 | 89.9 | 233 | 10.1 | |
| 3 | 904 | 89.1 | 108 | 10.9 | |
| Ki-67 | 0.033 | ||||
| <20% | 2868 | 92.3 | 239 | 7.7 | |
| ≥20% | 1224 | 90.4 | 130 | 9.6 | |
| Subtypes | 0.01 | ||||
| HRs(+) HER2(-) | 2448 | 91.8 | 198 | 8.2 | |
| HRs(+) HER2(+) | 846 | 88.0 | 115 | 12.0 | |
| HRs(-) HER2(+) | 326 | 91.1 | 32 | 8.9 | |
| HRs(-) HER2(-) | 553 | 93.9 | 36 | 6.1 | |
| Endocrine therapy | 0.283 | ||||
| No | 933 | 92.2 | 79 | 7.8 | |
| Yes | 3207 | 91.4 | 302 | 8.6 | |
| Herceptin treatment | <0.001 | ||||
| No | 3639 | 92.5 | 293 | 7.5 | |
| Yes | 466 | 86.9 | 70 | 13.1 | |
| Adjuvant Chemotherapy | <0.001 | ||||
| No | 2038 | 96.3 | 79 | 3.7 | |
| Yes | 2135 | 87.5 | 305 | 12.5 | |
| Radiotherapy | 0.011 | ||||
| No | 1314 | 93.2 | 96 | 6.8 | |
| Yes | 2859 | 90.9 | 285 | 9.1 | |
| Breast operation | <0.001 | ||||
| PM | 2643 | 93.0 | 199 | 7.0 | |
| TM | 1530 | 89.4 | 182 | 10.6 | |
| Axillary operation | <0.001 | ||||
| SLNB | 3504 | 94.8 | 193 | 5.2 | |
| SLNB+ALND | 669 | 78.1 | 188 | 21.9 | |
HRs, hormone receptor; HER2, human epidermal growth factor-2 receptor; PM, partial mastectomy; TM, total mastectomy; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection.